Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy‑naive advanced non-small cell lung cancer

Tas,Faruk; Sen,Fatma; Guney,Nese; Keskin,Serkan; Camlica,Hakan

doi:10.3892/ol.2013.1205

Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy‑naive advanced non-small cell lung cancer

Authors:
- Faruk Tas
- Fatma Sen
- Nese Guney
- Serkan Keskin
- Hakan Camlica
View Affiliations

Affiliations: Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul 34390, Turkey
Published online on: February 21, 2013 https://doi.org/10.3892/ol.2013.1205
Pages: 1699-1703

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The synergistic effects of new generation chemotherapeutics when combined with cisplatin have encouraged the development of new triplet combination regimens in the treatment of advanced non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the feasibility of triplet chemotherapy using weekly cisplatin-gemcitabine-docetaxel (CGD) for patients with chemotherapy-naive NSCLC. Twenty‑seven patients with stage IIIB/IV disease and performance status of 0 to 2 were included in this prospective trial. A combination of gemcitabine 750 mg/m2, cisplatin 25 mg/m2 and docetaxel 25 mg/m2 was administered on days 1, 8 and 15, with cycles repeated every 3 weeks. Leucopenia and/or neutropenia and to a lesser extent thrombocytopenia were the main dose-limiting toxicities. Grade III-IV neutropenia and thrombocytopenia occurred in 26 and 7% of the patients, respectively. Only one patient developed febrile neutropenia. Dose reductions were required in 26% of patients, delays in 44% of patients and early treatment discontinuation in 15% of patients. The overall response rate was 52% and all of them experienced a partial response. The median progression-free (PFS) and overall survival (OS) times were 6 and 13 months, respectively. The one-year survival rate was 46%. In conclusion, weekly administration of CGD is an active first-line therapy with acceptable toxicity in advanced NSCLC patients.

View Figures

View References

1	Marino P, Pampallona S, Preatoni A, Cantoni A and Invernizzi F: Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest. 106:861–865. 1994. View Article : Google Scholar : PubMed/NCBI
2	No authors listed. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 311:899–909. 1995. View Article : Google Scholar : PubMed/NCBI
3	Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, et al: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 18:623–631. 2000.
4	Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 12:360–367. 1994.PubMed/NCBI
5	Metro G, Cappuzzo F, Finocchiaro G, Toschi L and Crinò L: Development of gemcitabine in non-small cell lung cancer: the Italian contribution. Ann Oncol. 17:37–46. 2006. View Article : Google Scholar
6	Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM and Peters GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 2:521–530. 1996.PubMed/NCBI
7	Lippe P, Tummarello D, Monterubbianesi MC, Silva RR, Giuliodori L, Mari D, et al: Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study. Ann Oncol. 10:217–221. 1999. View Article : Google Scholar : PubMed/NCBI
8	Abratt RP, Bezwoda WR, Goedhals L and Hacking DJ: Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 15:744–749. 1997.PubMed/NCBI
9	Einhorn LH: Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol. 24:S824–S826. 1997.PubMed/NCBI
10	Crinò L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, et al: Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 15:297–303. 1997.
11	Chen SC, Lin MC, Chang JW, Wang SW, Lee CH and Tsao TC: Phase II study of regimen of gemcitabine and cisplatin in advanced non-small cell lung cancer. Jpn J Clin Oncol. 30:494–498. 2000. View Article : Google Scholar
12	Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, et al: Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer. 47:69–80. 2005.PubMed/NCBI
13	Crinò L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, et al: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol. 17:3522–3530. 1999.PubMed/NCBI
14	Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or meta-static non-small-cell lung cancer. J Clin Oncol. 18:122–130. 2000.PubMed/NCBI
15	Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar
16	Belani CP: Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer. Oncology. 11:42–45. 1997.PubMed/NCBI
17	Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
18	Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, et al: Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol. 22:254–261. 2004. View Article : Google Scholar : PubMed/NCBI
19	Sobin LH and Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI
20	Tabata M, Kozuki T, Ueoka H, Nicolella GP, Natale M, Pacilio C, et al: A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study. Cancer Chemother Pharmacol. 60:53–59. 2007. View Article : Google Scholar : PubMed/NCBI
21	Frasci G, Panza N, Comella P, Manzione L, De Cataldis G, Cioffi R, et al: Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study. Ann Oncol. 8:1045–1048. 1997. View Article : Google Scholar : PubMed/NCBI
22	Comella P, Frasci G, Panza N, Soria JC, Le Chevalier T and Pignon P: Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol. 18:1451–1457. 2000.
23	Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T and Pignon JP: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. 292:470–484. 2004. View Article : Google Scholar : PubMed/NCBI
24	Azim HA Jr, Elattar I, Loberiza FR Jr, Azim H, Mok T and Ganti AK: Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview. Lung Cancer. 64:194–198. 2009. View Article : Google Scholar : PubMed/NCBI
25	Li JL, Zhang XR, Liu JW, Fujiwara Y, Toyooka S and Umemura S: Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 28:309–312. 2006.(In Chinese).
26	Fujimoto N, Kiura K, Takigawa N, Kiura K, Harita S, Tada A, et al: Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer. Acta Med Okayama. 64:33–37. 2010.PubMed/NCBI